Media Coverage

The $409,000 contract will see Proteomics International test a novel drug for degenerative and infla...

“Proteomics followers have had plenty to read about this year with the company hitting a number of m...

“Study results have shown PromarkerD can outperformed the current tests used to predicting the onset...

World’s first predictive diagnostic test for diabetic kidney disease to be sold in Great Britain und...

“Apacor will become the exclusive distributor for PromarkerD in Great Britain (England, Scotland and...

“The distribution agreement provides medical diagnostics company, Apacor Limited with the right to s...

Proteomics International Managing Director Dr Richard Lipscombe said he was delighted to welcome Dr ...

Study shows PromarkerD is significantly better than current standard of care tests eGFR and ACR for ...

“The research, presented at Kidney Week 2021, the annual meeting of the American Society of Nephrolo...

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has been awarded a $1...

“Proteomics’ project, entitled ‘Manufacturing the next generation in vitro diagnostic device to pred...

“The findings demonstrate PromarkerD’s appeal to clinicians and payors in the management of diabetes...

Proteomics International has contracted French immunoassay specialist Biotem to manufacture test kit...

“An estimated 1.2 million Australians are living with diabetes, a serious chronic disease with numer...

“The company, Biotem, has been contracted to manufacture test kits for the PromarkerD predictive tes...

“An estimated 1.2 million Australians are living with diabetes, a serious chronic disease with numer...

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to provide...

Managing Director Richard Lipscombe was interviewed by ABC presenter Christine Layton on the WA Afte...

“The partnership aims to develop the world’s first blood test for the painful condition, which affec...

Proteomics International, the University of Melbourne and the Royal Women’s Hospital have today sign...

“The collaboration will look into biomarkers within the blood, described as ‘fingerprints’, specific...

“Listen to ASX-listed Proteomics International Managing Director, Richard Lipscombe talk to Matt Bir...

Global life science company Abcam plc has been engaged to produce reagents for Proteomics Internatio...

“According to the company, securing a supply agreement with Abcam and implementing other necessary p...

Proteomics International Laboratories Ltd today announces that its collaborative study with Janssen ...

Proteomics Managing Director Dr Richard Lipscombe said the study further validated PromarkerD.

Independent consultant Boston Healthcare Associates modelled the budget impact of using PromarkerD c...

“Research by independent consultant Boston Healthcare Associates modelling the budget impact of Prom...

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) today announced the e...

“The contract with Avance Clinical forms part of a phase one clinical trial that will look at the sa...

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has secured a major p...

Independent modelling estimates instigating PromarkerD testing could produce net savings for US payo...

513(g) application will allow Proteomics International to determine the best product classification ...

The Company is pleased to advise it has received ISO 13485 certification, the most widely-used inter...

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to report ...

“A significant problem among diabetic patients with kidney disease is a lack of symptoms. Most diabe...

“Proteomics expects to meet with the FDA to progress its clearance within 10 weeks. If PromarkerD ga...

“FDA sign off would assure potential licensing partners and consumers that the test has been develop...

Pre-submission package for diabetic kidney disease (DKD) test lodged with the US Food and Drug Admin...